Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Johnson and Johnson
AstraZeneca
Harvard Business School
Colorcon

Last Updated: December 6, 2022

CLINICAL TRIALS PROFILE FOR DURACLON


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Duraclon

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00349921 ↗ Clonidine Versus Adenosine to Treat Neuropathic Pain Completed National Institute of Neurological Disorders and Stroke (NINDS) Phase 2 2004-08-01 The purpose of this study is to determine the effects of clonidine and adenosine on nerve pain.
NCT00349921 ↗ Clonidine Versus Adenosine to Treat Neuropathic Pain Completed Wake Forest School of Medicine Phase 2 2004-08-01 The purpose of this study is to determine the effects of clonidine and adenosine on nerve pain.
NCT00349921 ↗ Clonidine Versus Adenosine to Treat Neuropathic Pain Completed Wake Forest University Health Sciences Phase 2 2004-08-01 The purpose of this study is to determine the effects of clonidine and adenosine on nerve pain.
NCT00510016 ↗ Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome Completed Johns Hopkins University Phase 2 2002-07-01 To test the hypothesis that the combination of the tincture of opium (DTO) and clonidine will be more effective in treating infants with neonatal abstinence syndrome (opioid withdrawal) than tincture of opium (DTO) alone.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Duraclon

Condition Name

Condition Name for Duraclon
Intervention Trials
Postoperative Pain 2
Neonatal Abstinence Syndrome 2
Pain Management 1
Total Hip and Knee Arthroplasty 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Duraclon
Intervention Trials
Pain, Postoperative 2
Neonatal Abstinence Syndrome 2
Opioid-Related Disorders 1
Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Duraclon

Trials by Country

Trials by Country for Duraclon
Location Trials
United States 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Duraclon
Location Trials
Maryland 3
Pennsylvania 1
New York 1
Tennessee 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Duraclon

Clinical Trial Phase

Clinical Trial Phase for Duraclon
Clinical Trial Phase Trials
Phase 4 3
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Duraclon
Clinical Trial Phase Trials
Completed 6
Terminated 2
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Duraclon

Sponsor Name

Sponsor Name for Duraclon
Sponsor Trials
Johns Hopkins University 3
National Institute on Drug Abuse (NIDA) 2
Gauda, Estelle B., M.D. 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Duraclon
Sponsor Trials
Other 14
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
McKesson
Mallinckrodt
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.